≥99% PURITY GUARANTEEDTHIRD-PARTY TESTEDSAME-DAY SHIPPING USACOA WITH EVERY ORDERFREE SHIPPING $200+

For research and educational purposes only. Not intended for human consumption.

SLU-PP-332

Limited Research
Updated Dec 2025

Synthetic Pan-ERR Agonist | Exercise Mimetic & Metabolic Modulator

Injectable
Did you know? You can to improve this page.
50 mg/kg (ANIMAL DOSING - NO HUMAN DOSE)
Twice daily (research protocol)
Injectable
Research compound - IP injection in animals only
4-8 weeks (preclinical studies)
Typical duration
Research
Storage

Overview

What is SLU-PP-332?

SLU-PP-332 is a synthetic small-molecule pan-estrogen-related receptor (ERR) agonist developed at Saint Louis University. Often called an 'exercise mimetic,' it activates metabolic pathways typically engaged during physical exercise. Studies show 12% weight loss in 28 days, 70% increased endurance, and enhanced insulin sensitivity. NOT FDA-APPROVED - FOR RESEARCH ONLY. Banned by WADA

Key Benefits

Exercise mimetic without physical activity, 12% weight loss (28 days animal studies), 70% increased endurance, 25% enhanced fatty acid oxidation, improved insulin sensitivity, cardiac protection.

Mechanism of Action

Binds to and activates ERRα/β/γ receptors, upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density up to 1.8-fold.

Molecular Information

290.32 Da
Weight
0
amino acids
Synthetic small molecule ERR agonist
Type
Amino Acid Sequence:
N/A - non-peptide small molecule
* Chemical formula: C₁₈H₁₄N₂O₂. NOT for human use - research only.

Pharmacokinetics

Peak
Variable
Half-life
Unknown in humans
Cleared
Unknown
100%50%0%0h6h12h18h24h
Peak
Half-life
Cleared
Preclinical studies only

Research Indications

Weight Loss

12% body weight reduction in 28 days in animal studies.

Insulin Sensitivity

Significantly improved glucose tolerance in obese mice.

Liver Health

Reduced hepatic steatosis and triglycerides.

Research Protocols

Disclaimer: NOT FDA APPROVED. NO HUMAN CLINICAL TRIALS. FOR RESEARCH USE ONLY. Human dosing does not exist.

GoalDoseFrequencyRoute
RESEARCH ONLY50 mg/kg (animal)Twice dailyIP injection (animals)
NO HUMAN DOSENOT ESTABLISHEDAwaiting clinical trialsOral formulation in development

Timing: Animal studies used IP injection twice daily. Human protocols DO NOT EXIST.

Peptide Interactions

How to Reconstitute

Important: Always use bacteriostatic water (BAC). Sterile technique is essential.

1

Insoluble in water - use DMSO

2

Dissolve in pure DMSO first (50-125 mg/mL)

3

Dilute: 10% DMSO + 10% Tween 80 + 80% PBS

4

Store DMSO stocks at -80°C

5

Final DMSO <10% for in vivo use

Dosing Calculator

Calculate your injection volume with visual dosing guide

FINAL CONCENTRATION
2.50mg/mL
Each milliliter contains 2.50 mg of peptide
VISUAL REFERENCE (RESEARCH USE ONLY)

To obtain 250 mcg from this solution:

Draw 0.10 mL=10 units

(1 mL = 100 units on any insulin syringe)

0102030405060708090100
00.10.20.30.40.50.60.70.80.91.0
0.10 mL
10 units

Draw to this mark for 250 mcg

This calculator is for research purposes only. Always verify calculations and consult protocols.

Quality Indicators

Insoluble in water

Must use DMSO as solvent, not BAC water.

Research chemical only

NOT FOR HUMAN USE - no human safety data.

Products for human consumption

Any product marketed for humans is illegal.

What to Expect

  • Hours 1-6: Metabolic shift toward fat oxidation
  • Week 1: Increased resting energy expenditure
  • Week 2-4: Weight loss, improved glucose tolerance
  • Week 6-8: Cardiac improvements, sustained metabolic benefits

Side Effects & Safety

Side Effects

  • NOT FDA APPROVED - RESEARCH ONLY
  • Human safety profile COMPLETELY UNKNOWN
  • Animal studies show favorable safety at therapeutic doses
  • No liver, kidney, or cardiac toxicity in animals
  • Legal status varies by jurisdiction

When to Stop

  • DO NOT USE - research chemical only
  • Await human clinical trials
  • Any adverse effects

References

2 Studies

ERR Agonist Alleviates Metabolic Syndrome (2024)

Mouse | 50 mg/kg | 28 days | 12% weight loss, improved glucose

Landmark study showing weight loss and metabolic improvements.

Exercise Mimetic Response (2023)

Mouse | Running performance | 70% endurance increase

First demonstration that ERR activation replicates exercise effects.

Quick Start Guide

Typical Dose
NO APPROVED HUMAN DOSE
How Often
NOT ESTABLISHED
Where to Inject
Research compound - IP in animals only
Timing
Awaiting human trials
Effects Timeline
Animal studies show effects in hours to weeks
Storage
Research compound requirements vary
Cycle Length
NOT ESTABLISHED
Break Between
UNKNOWN - no human data

Research Disclaimer

SLU-PP-332 is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving SLU-PP-332 must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of SLU-PP-332 for any purpose. Consult qualified professionals for any research applications.